A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy

[1]  B. Bielekova,et al.  An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK Cells , 2010, The Journal of Immunology.

[2]  Xavier Montalban,et al.  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta , 2010, The Lancet Neurology.

[3]  M. Burns,et al.  24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury , 2010, Brain Research.

[4]  G. Pantaleo,et al.  IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. , 2009, The Journal of allergy and clinical immunology.

[5]  T. Waldmann,et al.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. , 2009, Archives of neurology.

[6]  H. McFarland,et al.  Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. , 2009, Archives of neurology.

[7]  Y. Lebranchu,et al.  Anti-CD25 antibodies decrease the ability of human dendritic cells to prime allogeneic CD4 T cells. , 2009, Transplantation proceedings.

[8]  R. Oueslati,et al.  Anti‐CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells , 2008, Journal of leukocyte biology.

[9]  T. Malek,et al.  The biology of interleukin-2. , 2008, Annual review of immunology.

[10]  R. Oueslati,et al.  Anti CD25 treatment of human dendritic cells modulates both their cytokine synthesis profiles and their capacity to activate allogeneic CD4 T cells: a potential tolerogenic effect. , 2008, International immunopharmacology.

[11]  Dolca Thomas,et al.  Tonsilar NK Cells Restrict B Cell Transformation by the Epstein-Barr Virus via IFN-γ , 2008, PLoS pathogens.

[12]  J. Rose,et al.  Daclizumab phase II trial in relapsing and remitting multiple sclerosis , 2007, Neurology.

[13]  David L. Williams,et al.  Syk‐dependent ERK activation regulates IL‐2 and IL‐10 production by DC stimulated with zymosan , 2007, European journal of immunology.

[14]  S. Goerdt,et al.  Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells. , 2007, Molecular immunology.

[15]  A. Caudy,et al.  CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. , 2007, The Journal of allergy and clinical immunology.

[16]  I. Mackay,et al.  IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. , 2006, Journal of autoimmunity.

[17]  J. Freedman,et al.  Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells , 2006, Nature Medicine.

[18]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Garcia,et al.  Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γc Receptors , 2005, Science.

[20]  Shimon Sakaguchi,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[21]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Ricciardi-Castagnoli,et al.  Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity , 2003, The EMBO journal.

[23]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[24]  Maria Persico,et al.  Inducible IL-2 production by dendritic cells revealed by global gene expression analysis , 2001, Nature Immunology.

[25]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[26]  C. Roifman.  Human IL-2 Receptor α Chain Deficiency , 2000, Pediatric Research.

[27]  T. Waldmann,et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Waldmann,et al.  The use of antibodies against the IL-2 receptor in transplantation. , 1998, Current opinion in immunology.

[29]  V. Kronin,et al.  Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? , 1998, International immunology.

[30]  H. Dadi,et al.  Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor , 1997 .

[31]  F. Alt,et al.  Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. , 1995, Immunity.

[32]  M. Lenardo.  lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[33]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[34]  W. Leonard,et al.  Signaling via the IL-2 and IL-7 receptors from the membrane to the nucleus. , 1999, Cold Spring Harbor symposia on quantitative biology.